First human test of cancer drug for Tough-to-Treat leukemias
NCT ID NCT03042689
Summary
This early-stage study aimed to find the safest and most effective dose of the drug regorafenib for adults with advanced blood cancers that have returned or stopped responding to standard treatments. It involved 16 participants with conditions like acute myeloid leukemia. The main goal was to understand the drug's side effects and how well it might control the disease before planning larger studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts general Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.